Psoriatic arthritis

07-12-2018 | Psoriatic arthritis | Article

Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study

Coates LC et al. Arthritis Res Ther 2018; 20: 272. doi: 10.1186/s13075-018-1773-y

31-10-2018 | Psoriatic arthritis | ACR/ARHP 2018 | Article

From the Editorial Board: Highlights from the 2018 ACR/ARHP Annual Meeting

Editorial board members Oliver FitzGerald and Fernando Pérez-Ruiz provide their highlights from the spondyloarthropathy and crystal arthropathy sessions at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA.

13-06-2018 | Psoriatic arthritis | Review | Article

Ustekinumab in psoriatic arthritis and related phenotypes

Dobbins-Sears I et al. Ther Adv Chronic Dis 2018; 9: 191–198. doi: 10.1177/2040622318781760

16-10-2018 | Psoriatic arthritis | Review | Article

Efficacy of new treatments for dactylitis of psoriatic arthritis: Update of literature review

Sondag M et al. Clin Rheumatol 2018. doi: 10.1007/s10067-018-4328-3

15-09-2018 | Psoriatic arthritis | Article

The effect of pregnancy on disease activity in patients with psoriatic arthritis

Berman M et al. J Rheumatol 2018. doi: 10.3899/jrheum.171218

07-09-2018 | Psoriatic arthritis | Article

Disease activity of psoriatic arthritis during and after pregnancy: A prospective multicenter study

Ursin K et al. Arthritis Care Res 2018. doi: 10.1002/acr.23747

01-09-2018 | DMARDs | Review | Article

A practical approach to the use of conventional synthetic, biologic, and targeted synthetic disease modifying anti-rheumatic drugs for the treatment of inflammatory arthritis in patients with a history of malignancy

Wong PKK et al. Curr Rheumatol Rep 2018; 20: 64. doi: 10.1007/s11926-018-0774-9

01-09-2018 | Psoriatic arthritis | Article

Incidence and predictive factors for orthopedic surgery in patients with psoriatic arthritis

Nystad TW et al. J Rheumatol 2018. doi: 10.3899/jrheum.180203

29-08-2018 | Psoriatic arthritis | Article

Safety of ixekizumab in patients with psoriatic arthritis: Results from a pooled analysis of three clinical trials

Mease P et al. Arthritis Care Res 2018. doi: 10.1002/acr.23738

21-08-2018 | DMARDs | Article

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis: Executive summary

Holroyd CR et al. Rheumatology (Oxford) 2018: key207. doi: 10.1093/rheumatology/key207

21-08-2018 | DMARDs | Article

The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis

Holroyd CR et al. Rheumatology (Oxford) 2018: key207. doi: 10.1093/rheumatology/key208

21-08-2018 | Psoriatic arthritis | Article

Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumor-necrosis factor alpha inhibition: Results from the British Society for Rheumatology Biologics Register

Fagerli KM et al. Rheumatology (Oxford) 2018: key241. doi: 10.1093/rheumatology/key241

20-08-2018 | Nursing | Review | Article

Nurses’ roles in the management of chronic inflammatory arthritis: A systematic review

Vivienne L, Michael S. Rheumatol Int 2018. doi: 10.1007/s00296-018-4135-9

09-08-2018 | Physical activity | Article

The prevalence of co-morbidities and their impact on physical activity in people with inflammatory rheumatic diseases compared with the general population: Results from the UK Biobank

Cook MJ et al. Rheumatology (Oxford) 2018: key224. doi: 10.1093/rheumatology/key224

06-08-2018 | TNF inhibitors | Review | Article

Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: Systematic review of randomized controlled trials and real-world studies

Numan S, Faccin F. Adv Ther 2018; 9: 1295–1332. doi: 10.1007/s12325-018-0742-9

04-08-2018 | Biologics | Review | Article

A targeted literature review examining biologic therapy compliance and persistence in chronic inflammatory diseases to identify the associated unmet needs, driving factors, and consequences

Maniadakis N et al. Adv Ther 2018; 9: 1333–1355. doi: 10.1007/s12325-018-0759-0

24-07-2018 | Psoriatic arthritis | Article

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: Week 52 results from SPIRIT-P2

Genovese MC et al. Rheumatology (Oxford) 2018: key182. doi: 10.1093/rheumatology/key182

27-07-2018 | Psoriatic arthritis | Article

Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: Results from the prospective PSARTROS study

Kampylafka E et al. Arthritis Res Ther 2018; 20: 153. doi: 10.1186/s13075-018-1653-5

18-07-2018 | Medications | Article

Dual inhibition of tumour necrosis factor and interleukin-17A with ABT-122: Open-label long-term extension studies in rheumatoid arthritis or psoriatic arthritis

Genovese MC et al. Rheumatology (Oxford) 2018: key173. doi: 10.1093/rheumatology/key173

13-07-2018 | Psoriatic arthritis | Article

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab

Behrens F et al. Rheumatology (Oxford) 2018: key203. doi: 10.1093/rheumatology/key203

Medicine Matters Rheumatology